S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Repligen Stock Forecast, Price & News

+5.32 (+2.57 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $212.39
50-Day Range
MA: $213.55
52-Week Range
Now: $212.39
Volume345,618 shs
Average Volume380,833 shs
Market Capitalization$11.18 billion
P/E Ratio259.01
Dividend YieldN/A
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Repligen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:RGEN
Year FoundedN/A



Sales & Book Value

Annual Sales$270.24 million
Cash Flow$1.44 per share
Book Value$20.36 per share


Net Income$21.41 million


Market Cap$11.18 billion
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.53 out of 5 stars

Medical Sector

420th out of 1,956 stocks

Biological Products, Except Diagnostic Industry

56th out of 177 stocks

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
+5.32 (+2.57 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Repligen (NASDAQ:RGEN) Frequently Asked Questions

Is Repligen a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen
or view top-rated stocks.

What stocks does MarketBeat like better than Repligen?

Wall Street analysts have given Repligen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Repligen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Repligen

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.21. Repligen had a net margin of 13.40% and a trailing twelve-month return on equity of 6.58%.
View Repligen's earnings history

How has Repligen's stock been impacted by COVID-19 (Coronavirus)?

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 133.4% and is now trading at $212.39.
View which stocks have been most impacted by COVID-19

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $1.86-$1.94 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.65. The company issued revenue guidance of $500-$525 million, compared to the consensus revenue estimate of $459.50 million.

What price target have analysts set for RGEN?

5 brokerages have issued 1-year price objectives for Repligen's shares. Their forecasts range from $150.00 to $251.00. On average, they expect Repligen's share price to reach $204.75 in the next year. This suggests that the stock has a possible downside of 3.6%.
View analysts' price targets for Repligen
or view top-rated stocks among Wall Street analysts.

Who are Repligen's key executives?

Repligen's management team includes the following people:
  • Mr. Anthony J. Hunt, CEO, Pres & Director (Age 57, Pay $1.52M)
  • Mr. Jon K. Snodgres, Chief Financial Officer (Age 55, Pay $638.09k)
  • Mr. Ralf Kuriyel, Sr. VP of R&D (Age 62, Pay $567.8k)
  • Mr. Jim Bylund, Sr. VP of Operations & Information Technology
  • Ms. Sondra S. Newman, Global Head of Investor Relations
  • Mr. Squire Servance, Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Stephen Tingley, VP of Global Sales
  • Ms. Rachel Goodrich, VP of Marketing
  • Mr. Ken Elmer, Global Head of HR
  • Ms. Christine Gebski, Sr. VP of Filtration & Chromatography

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), The Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of retail and institutional investors. Top institutional investors include Select Equity Group L.P. (2.35%), Price T Rowe Associates Inc. MD (2.26%), Alliancebernstein L.P. (2.06%), Bank of New York Mellon Corp (1.97%), Conestoga Capital Advisors LLC (1.94%) and Federated Hermes Inc. (1.31%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen

Which major investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Schroder Investment Management Group, Conestoga Capital Advisors LLC, Meritage Portfolio Management, Panagora Asset Management Inc., Tygh Capital Management Inc., and Alliancebernstein L.P.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen
or view top insider-selling stocks.

Which major investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Ardevora Asset Management LLP, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Thornburg Investment Management Inc., SG Americas Securities LLC, Penserra Capital Management LLC, and Stanley Laman Group Ltd..
View insider buying and selling activity for Repligen
or or view top insider-buying stocks.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $212.39.

How much money does Repligen make?

Repligen has a market capitalization of $11.18 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 761 workers across the globe.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

Where are Repligen's headquarters?

Repligen is headquartered at 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]

This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.